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KEY MESSAGE
Tubal flushing with oil-based contrast, compared with water-based contrast, had equivalent 5-year follow-up 
costs for a 7.5% increase in live birth rate. The increased price of oil-based contrast medium was compensated 
by a lower IVF uptake. The authors recommend it as the preferred strategy for tubal testing in infertile women 
with unexplained infertility.
 RBMO  VOLUME 42  ISSUE 1  2021 151
ABSTRACT
Research question: What are the long-term costs and effects of oil- versus water-based contrast in infertile women 
undergoing hysterosalpingography (HSG)?
Design: This economic evaluation of a long-term follow-up of a multicentre randomized controlled trial involved 1119 
infertile women randomized to HSG with oil- (n = 557) or water-based contrast (n = 562) in the Netherlands.
Results: In the oil-based contrast group, 39.8% of women needed no other treatment, 34.6% underwent intrauterine 
insemination (IUI) and 25.6% had IVF/intracytoplasmic sperm injection (ICSI) in the 5 years following HSG. In the water-
based contrast group, 35.0% of women had no other treatment, 34.2% had IUI and 30.8% had IVF/ICSI in the 5 years 
following HSG (P = 0.113). After 5 years of follow-up, HSG using oil-based contrast resulted in equivalent costs (mean 
cost difference –€144; 95% confidence interval [CI] –€579 to +€290; P = 0.515) for a 5% increase in the cumulative 
ongoing pregnancy rate compared with HSG using water-based contrast (80% compared with 75%, Relative Risk 
(RR) 1.07; 95% CI 1.00–1.14). Similarly, HSG with oil-based contrast resulted in equivalent costs (mean cost difference 
–€50; 95% CI –€576 to +€475; P = 0.850) for a 7.5% increase in the cumulative live birth rate compared with HSG 
with water-based contrast (74.8% compared with 67.3%, RR 1.11; 95% CI 1.03–1.20), making it the dominant strategy. 
Scenario analyses suggest that the oil-based contrast medium is the dominant strategy up to a price difference of €300.
Conclusion: Over a 5-year follow-up, HSG with an oil-based contrast was associated with a 5% increase in ongoing 
pregnancy rate, a 7.5% increase in live birth rate and similar costs to HSG with water-based contrast.
INTRODUCTION
T raditionally, assessment of the Fallopian tubes is an important part of the fertility workup in infertile women. 
Hysterosalpingography (HSG) is one of the 
most commonly applied outpatient clinic 
tubal patency tests in many countries and 
can be performed with either oil-based 
or water-based contrast medium (Cundiff 
et al., 1995). HSG was initially introduced 
as a diagnostic test, but possible 
therapeutic effects of tubal flushing have 
been suggested in literature for many 
years, especially with the use of oil-based 
contrast (Mohiyiddeen et al., 2015; Watson 
et al., 1994; Weir and Weir, 1951,).
In 2017, a large randomized controlled 
trial (RCT) in the Netherlands, the H2Oil 
study, confirmed that HSG with oil-based 
contrast (Lipiodol Ultra-Fluid; Guerbet, 
France) resulted in 10% higher 6-month 
ongoing pregnancy and live birth rates 
compared with HSG with water-based 
contrast (Telebrix Hystero; Guerbet, 
France) (Dreyer et al., 2017). A cost-
effectiveness analysis of the H2Oil study 
showed that HSG using an oil-based 
contrast was a cost-effective strategy 
after a 6-month (short-term) follow-up, 
with an incremental cost of US$8198 
for an additional ongoing pregnancy 
compared with HSG using a water-based 
contrast (van Rijswijk et al., 2018).
Considering these results, tubal flushing 
with oil-based contrast is gaining 
popularity, and two meta-analyses have 
recently been published on this topic 
(Fang et al., 2018; Wang et al., 2019). 
However, the follow-up duration of 
the included studies varies widely, and 
none of the included studies addressed 
the possible long-term effects of tubal 
flushing. Evidence regarding long-term 
fertility-enhancing effects of tubal flushing 
was insufficient until recently. In 2020 
van Rijswijk and colleagues published 
the H2Oil long-term follow-up study, 
comparing the effects of oil- versus 
water-based contrast medium at HSG 
up to 5 years after randomization in the 
H2Oil study (van Rijswijk et al., 2020). 
This follow-up study showed a higher 
5-year cumulative ongoing pregnancy 
rate, a shorter time to pregnancy and a 
higher chance of a natural conception 
in favour of oil-based contrast up to 5 
years after randomization. However, the 
long-term costs and effects of oil-based 
contrast have not yet been studied. The 
control of costs is important to facilitate 
access to effective fertility care. In view of 
increasing healthcare costs (Organisation 
for Economic Co-operation and 
Development, 2017), it is important to 
investigate and compare the long-term 
costs and effects of the two different 
types of contrast medium. The aim of 
this study is to assess the long-term 
costs and effects of HSG with oil-based 
contrast versus water-based contrast in a 
long-term cost-effectiveness analysis.
MATERIALS AND METHODS
This study involved an economic 
evaluation of the long-term follow-
up of the H2Oil study (Netherlands 
Trial Register (NTR) 6577, http://www.
trialregister.nl) of participants in the 
H2Oil study (NTR 3270). Reproductive 
outcome data up to 5 years after 
randomization were collected. Details 
of the H2Oil study and H2Oil follow-up 
study have been published elsewhere 
(Dreyer et al., 2017; van Rijswijk et al., 
2020). This study was investigator 
initiated, and the research protocol was 
approved by the Institutional Review 
Board of the Amsterdam University 
Medical Centre – VU University Medical 
Centre (reference 2017.221, dated 14 
June 2017). In this article, the trial 
essentials are briefly discussed.
Patients and study procedures
Infertile women between 18 and 39 years 
of age with an ovulatory cycle and an 
indication for tubal patency testing by 
HSG were eligible for the H2Oil study. 
Couples with male infertility (total motile 
sperm count after sperm washing of less 
than 3 million spermatozoa per millilitre), 
endocrine disorders (e.g. polycystic ovary 
syndrome, diabetes, hyperthyroidism 
or hyperprolactinaemia), iodine allergy 
or a high risk of tubal pathology (a 
history of pelvic inflammatory disease, 
previous Chlamydia infection or 
known endometriosis) were excluded. 
After informed consent, women were 
randomized to the use of oil-based 
contrast (Lipiodol Ultra Fluid; Guerbet, 
France) or water-based contrast (Telebrix 
Hystero; Guerbet, France) during HSG 
in a 1:1 ratio, and HSG was performed 
according to local protocols (Dreyer 
et al., 2017; van Rijswijk et al., 2020).
Infertility treatments
Fertility treatment advice within the 12 
months after HSG was based on the 
standard Hunault prediction for natural 
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conception (Hunault et al., 2005). 
This prognostic model is widely used 
in the Netherlands as a decision aid. 
Depending on the results of the HSG, 
women received expectant management 
for 6 months if their prognosis for 
natural conception was good (>30% in 
12 months), or underwent intrauterine 
insemination (IUI) if their prognosis for 
natural conception was less than 30% or 
6 months of expectant management had 
elapsed (Hunault et al., 2005). Women 
underwent IVF/intracytoplasmic sperm 
injection (ICSI) if there was bilateral tubal 
occlusion, semen analysis during IUI 
showed very poor semen quality or there 
had been six failed IUI cycles (van Rijswijk 
et al., 2020). The main outcome was first 
ongoing pregnancy after HSG, defined as 
a positive fetal heartbeat on ultrasound 
after 12 weeks of gestation. Secondary 
outcomes were live birth, defined as a 
live birth after 24 weeks of gestation, 
multiple pregnancy rate and miscarriage 
rate. Additional secondary outcomes 
measured in the H2Oil study were not 
considered in this economic evaluation.
Economic evaluation
The economic evaluation was performed 
from the healthcare system perspective. 
The analysis was conducted according 
to the International Society for 
Pharmacoeconomics and Outcomes 
Research (ISPOR) guidelines (McGhan 
et al., 2009), and the report followed 
the Consolidated Health Economic 
Evaluation Reporting Standards 
statement (Husereau et al., 2013).
For the primary outcome of first ongoing 
pregnancy leading to live birth, the total 
direct medical costs for each participant 
included those for the contrast medium 
intervention and infertility treatments 
and miscarriage in the 5 years since 
randomization. An additional analysis 
included the direct medical costs related 
to pregnancy and delivery to assess the 
costs associated with achieving a live 
birth.
Data on resource use were obtained 
by reviewing each participant's 
electronic medical records; in addition, 
a questionnaire was sent to all H2Oil 
participants to collect information 
supplementary to their medical record 
(van Rijswijk et al., 2020). For each 
participant, the type and number of 
interventions received either until the 
first ongoing pregnancy or within 5 years 
since randomization were registered, as 
was whether a single or multiple (twin) 
live births were achieved. The costs 
for each parameter were derived from 
three previous publications (Graziosi 
et al., 2005; Lukassen et al., 2004; 
Tjon-Kon-Fat et al., 2015). The costs for 
the contrast media were provided by 
the manufacturer (Guerbet, France). 
The cost parameters and unit costs 
included in the economic evaluation 
for the follow-up study (expressed 
in euros) are presented in TABLE 1. All 
calculations were standardized to 2018 
prices using consumer price index data. 
Three main cost categories were used: 
contrast media, infertility treatments, and 
pregnancy and delivery or miscarriage.
Statistical analysis
The mean costs and outcomes for 
each treatment group were compared. 
Incremental cost-effectiveness ratios 
and 95% confidence intervals (CI) were 
calculated by dividing the difference in 
total costs by the difference in outcome 
between the two groups. Bootstrapping 
(using 1000 resamples) was used to 
represent the joint uncertainty around 
the incremental costs and outcomes. A 
cost-effectiveness plane was generated 
to graphically represent the difference in 
costs and outcomes between oil-based 
and water-based contrast media and the 
uncertainty around the expected costs 
and expected effects associated with 
each intervention. Cost-effectiveness 
acceptability curves were also generated 
to indicate the probability that use of 
the oil-based contrast medium would 
be cost-effective compared with water-
based contrast medium for a range of 
values representing the willingness to 
pay for ongoing pregnancy and live birth. 
Statistical analyses were performed using 
Stata Statistical Software, version 15 
(StataCorp, USA) and Microsoft Excel 
2016 (Microsoft Corporation, USA). Data 
were analysed using the intention to treat 
principle.
Scenario analyses
As a comparison, scenario analyses were 
undertaken to determine the impact of 
the difference in contrast media cost on 
the cost-effectiveness. The base case 
difference in the costs of the contrast 
media was €213, values ranging from €0 
to €500 were tested.
RESULTS
Study population
Between February 2012 and October 
2014, 1119 women were randomly 
assigned to HSG with oil-based contrast 
(n = 557) or water-based contrast 
(n = 562). The baseline characteristics 
were similar across the two groups 
(Supplementary Table S1). Five women 
were lost to follow-up within the first 
6 months: two from the oil group and 
three from the water group. Due to the 
low number of missing values, missing 
data were not imputed. Thus, the 
analyses were undertaken on 555 women 
in the oil group and 559 women in the 
water group (1114 in total).
Participants’ characteristics and trial 
follow-up outcomes, including infertility 
treatments after HSG, are summarized 
in Supplementary Table S1. Of the 
women in the oil-based contrast medium 
group, 39.8% had no other treatment, 
TABLE 1 UNIT COSTS FOR THE CONTRAST MEDIUM INTERVENTION, 
INFERTILITY TREATMENTS, AND PREGNANCY AND DELIVERY OR 
MISCARRIAGE (€)
Characteristics Unit costs (€) Source
Contrast medium
 Oil-based contrast 225 Guerbet, France
 Water-based contrast 12 Guerbet, France
Infertility treatments
 Intrauterine insemination 300 Tjon-Kon-Fat et al. (2015)
 IVF 3,000 Tjon-Kon-Fat et al. (2015)
 Intracytoplasmic sperm injection 3,300 Tjon-Kon-Fat et al. (2015)
Pregnancy and delivery
 Singleton 3,320 Lukassen et al. (2004)
 Twin 17,540 Lukassen et al. (2004)
Miscarriage (dilation and curettage) 1,730 Graziosi et al. (2005)
Unit costs indexed to 2018 Euro prices.
 RBMO  VOLUME 42  ISSUE 1  2021 153
34.6% underwent IUI and 25.6% had 
IUI followed by IVF/ICSI or IVF/ICSI 
alone in the 5 years following HSG. In 
comparison, of the women in the water-
based contrast medium group, 35.0% 
had no other treatment, 34.2% had IUI 
and 30.8% had IUI followed by IVF/ICSI 
or IVF/ICSI alone in the 5 years following 
HSG (P = 0.113). The ongoing pregnancy 
rates within the 5 years were 80% in 
the oil-based contrast group and 75% in 
the water-based contrast group (Relative 
Risk (RR) 1.07; 95% CI 1.00–1.14). The 
live birth rates within the 5 years were 
75% in the oil-based contrast group and 
67% in the water-based contrast group 
(RR 1.11; 95% CI 1.03–1.20). Information 
on live birth was missing in 20 ongoing 
pregnancies in the oil group versus 33 
ongoing pregnancies in the water group. 
The multiple pregnancy and miscarriage 
rates within the 5 years were low and did 
not differ significantly. Median follow-
up was 45.3 months in the oil-based 
contrast group and 46.7 months in the 
water-based contrast group.
Costs and effects (oil-based contrast 
versus water-based contrast)
After 5 years of follow-up, the difference 
in the proportion of women with an 
ongoing pregnancy was 5.0% (95% CI 
0.03–9.9%; 80.0% in the oil group versus 
75.0% in the water group) and with a live 
birth was 7.5% (95% CI 2.1–12.5%; 74.8% 
in the oil group versus 67.3% in the water 
group).
A comparison of the mean costs per 
woman by cost category for the two 
treatment groups is provided in TABLE 2. 
The mean costs per woman were lower 
in the oil-based contrast group than 
in the water-based contrast group for 
ongoing pregnancy (mean cost difference 
–€144; 95% CI –€579 to +€290; 
P = 0.515). For the oil-based group, the 
higher cost for the contrast medium 
(€225) was offset by more women 
requiring no other treatment (i.e. 39.8% 
conceived naturally) and fewer women 
having IVF/ICSI (25.6%). The water-based 
group had a lower contrast medium cost 
(€12) but more women had IVF/ICSI 
(30.8%) and fewer women conceived 
naturally (35.0%). The proportion of 
women having IUI was similar across the 
two treatment groups.
Similarly, for live birth, the mean costs 
per woman were lower in the oil-based 
contrast group than in the water-based 
contrast group (mean cost difference 
–€50; 95% CI –€576 to +€475; 
P = 0.850). The smaller difference in 
mean costs was due to the increased 
costs for pregnancy and delivery as a 
result of the increase in live births in 
the oil-based group. Thus, after 5 years 
of follow-up, HSG using an oil-based 
contrast medium was considered the 
dominant strategy over HSG using a 
water-based contrast medium, with 
comparable costs and higher ongoing 
pregnancy and live birth rates.
The bootstrap samples were located in 
the eastern quadrants, indicating that 
there is little uncertainty regarding the 
effectiveness of the oil-based contrast 
medium (FIGURE 1). The spread of the 
bootstrap samples across the north and 
south-eastern quadrants indicates that 
there is uncertainty regarding the cost 
difference between women receiving 
water- and oil-based contrast media 
(FIGURE 1). Given the cost-effectiveness 
acceptability curves presented in 
FIGURE 2, if the maximum acceptable 
ratio is €4000 per additional ongoing 
pregnancy or live birth, the probability 
that the use of an oil-based contrast 
medium is cost-effective compared with 
a water-based contrast medium is 0.9. 
Alternatively, this can be interpreted 
as there being a 90% chance that the 
potential additional cost of an oil-based 
contrast medium, compared with a 
water-based contrast medium, is less 
than €4000 per additional ongoing 
pregnancy or live birth. The costs 
associated with pregnancy and delivery 
had the greatest impact on the cost-
effectiveness of the oil-based contrast 
medium compared with the water-based 
contrast medium (TABLE 2).
Scenario analyses
The impact of the difference in contrast 
media costs on cost-effectiveness is 
presented in Supplementary Table S2. 
If there is no difference in the cost of 
contrast medium, the oil-based contrast 
medium is the dominant strategy for 
both ongoing pregnancy and live birth 
until a cost difference of €300, at which 
the oil-based contrast medium is no 
longer less costly and more effective, with 
a mean incremental cost-effectiveness 
ratio of €493 for an additional live birth.
DISCUSSION
An economic evaluation was performed 
alongside a long-term follow-up study 
of an RCT including infertile women 
scheduled for HSG with oil-based versus 
water-based contrast medium during 
a fertility workup. Women allocated to 
HSG with oil-based contrast medium had 
higher ongoing pregnancy and live birth 
rates than women allocated to HSG with 
water-based contrast for equivalent costs. 
After 5 years of follow-up, HSG with 
oil-based contrast resulted in equivalent 
costs (mean cost difference –€144; 95% 
CI –€579 to +€290; P = 0.515) for a 5% 
higher cumulative ongoing pregnancy 
rate. Similarly, HSG with oil-based 
contrast lead to equivalent costs (mean 
cost difference –€50; 95% CI –€576 
to +€475; P = 0.850) for a 7.5% higher 
cumulative live birth rate compared with 
HSG with water-based contrast. These 
TABLE 2 COMPARISON OF MEAN COSTS PER WOMAN FOR THE TWO TREATMENT GROUPS IN EUROS
Cost parameter Oil group (n = 555) (€) Water group (n = 559) (€) Mean difference (95% CI), 
P-value (€)
Contrast medium 225 12 213
Infertility treatments 2102 (3539) 2459 (3848) –357 (–792 to 77), P = 0.107
Total costs (for ongoing pregnancy) 2327 (3539) 2471 (3848) –144 (–579 to 290), P = 0.515
Miscarriage 212 (568) 254 (613) –42 (–111 to 28), P = 0.238
Pregnancy and delivery 2713 (2388) 2577 (2859) 136 (–174 to 446), P = 0.390
Total costs (for live birth) 5252 (4062) 5302 (4833) –50 (–576 to 475), P = 0.850
Data are presented as mean and standard deviation, unless otherwise specified.
CI, confidence interval.
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FIGURE 1 The cost-effectiveness plane representing the costs and effects of the oil-based contrast medium relative to the water-based contrast 
medium and the uncertainty around the incremental cost-effectiveness ratios. Estimates in the north-western quadrant of the cost-effectiveness 
plane indicate that the intervention is less effective and more costly; estimates in the south-western quadrant indicate that it is less effective and 
less costly; estimates in the south-eastern quadrant indicate that is is more effective and less costly; and estimates in the north-eastern quadrant 
indicate that it is more effective and more costly. Closed circles represent the base case incremental cost-effectiveness ratio (ICER) estimate; open 
circles represent the uncertainty around each ICER.
FIGURE 2 Cost-effective acceptability curves for ongoing pregnancy and live birth, indicating the probability that using oil-based contrast medium 
is cost-effective regarding ongoing pregnancy (dotted lines) and live birth (solid lines) after 3–5 years of follow-up, given alternative monetary 
values.
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differences make HSG with oil-based 
contrast the dominant strategy in infertile 
women with unexplained or mild male 
factor infertility.
This study has several strengths, but also 
some limitations. Its main strength is 
that this follow-up study was based on 
a large multicentre RCT investigating 
the effects of oil-based versus water-
based contrast with prospective and 
retrospective registration of resource 
use. The lost to follow-up at 6 months 
was lower in this follow-up study (two in 
the oil group versus three in the water 
group) than in the original H2Oil trial 
(five in the oil group versus 11 in the 
water group), so more data were available 
combining information from the medical 
files and the returned questionnaires. 
Furthermore, studies regarding the 
long-term costs and effects of oil- versus 
water-based contrast were lacking, and 
this study contributes to the counselling 
of couples undergoing tubal patency 
testing during fertility workup as well 
as giving guidance to healthcare policy 
makers.
A limitation of the study is that data 
regarding the long-term follow-up were 
collected retrospectively by reviewing 
medical files and sending women a 
questionnaire, resulting in variable 
durations of follow-up. However, 
the median time to follow-up was 
comparable between the two groups, 
which allowed a comparison between 
absolute ongoing pregnancy and live 
birth rates. Furthermore, information 
on live birth was missing in 20 ongoing 
pregnancies in the oil group versus 33 
ongoing pregnancies in the water group, 
either because there was no response 
on the questionnaire or because the 
woman was still pregnant at time of 
data collection. If it is assumed that all 
who were missing had a live birth, the 
difference in live birth between the oil 
and water groups would be 5% (the same 
as the difference in ongoing pregnancy), 
and the costs for pregnancy and delivery 
would increase accordingly.
Second, this economic evaluation 
focused on the direct medical costs 
and did not include potential indirect 
costs for patients and society (e.g. 
loss of productivity during pregnancy 
and delivery) as these data were not 
collected during the trial follow-up. It 
might be expected that, over a 3- to 
5-year period, the cost difference could 
increase in the case of more ongoing 
pregnancies and subsequently more 
hospital visits, transportation costs and 
productivity loss. On the other hand, 
visiting a fertility clinic and undergoing 
assisted reproductive technology (ART) 
also increases transportation costs and 
productivity loss.
Third, as this study was executed in the 
Netherlands, Netherlands-based costs 
were used. The price difference between 
oil-based and water-based contrast 
media was €213 (€225 versus €12). 
Globally, however, the cost differences 
of the two contrast media vary widely, 
thus limiting the generalizability of the 
data. Therefore, scenario analyses were 
performed illustrating the impact of the 
difference in contrast medium cost on 
cost-effectiveness, to make the results 
data applicable to other countries. HSG 
with oil-based contrast is cost-effective 
with a price difference of €300 or lower. 
However, in countries with high price 
differences, HSG with oil-based contrast 
is less cost-effective, and implementation 
depends on what society is willing to pay 
for an additional child.
Fourth, this study was limited to women 
at low risk of tubal pathology, less than 
39 years of age and with no known 
endocrinological diseases. The findings 
should therefore not be generalized to 
other groups of infertile women.
A comparison of the results can be made 
with those of other studies. At 6 months, 
HSG using oil-based contrast is a cost-
effective strategy compared with the 
use of water-based contrast, if society is 
willing to pay US$8198 per extra ongoing 
pregnancy (van Rijswijk et al., 2018). The 
cost difference between the two types 
of contrast media is globally the highest 
in the USA (US$900), and ART costs in 
the USA are much higher than those in 
Europe. HSG using oil-based contrast 
leads to more natural and IUI-conceived 
pregnancies and fewer IVF or ICSI-
conceived pregnancies in the long term. 
The cost-effectiveness of this strategy 
would be largely influenced by the costs 
of the oil-based contrast medium and 
the healthcare costs associated with 
pregnancy and delivery.
Two studies have evaluated the cost-
effectiveness of tubal patency testing 
during fertility workup (Mol et al., 2001; 
Verhoeve et al., 2013). Both studies 
evaluated different scenarios for the live 
birth rate within 3 years after fertility 
workup, i.e. expectant management 
without diagnostics, immediate IVF 
without diagnostics, delayed IVF without 
diagnostics, HSG and IVF, laparoscopy 
and IVF, etc. Mol and colleagues 
found Chlamydia antibody testing 
during fertility workup to be less costly 
compared with HSG in women with 
a good fertility prospects, whereas 
immediate HSG was advised in women 
with relatively poor fertility prospects 
(Mol et al., 2001). Verhoeve and co-
workers found that not performing 
a diagnostic tubal patency test but 
delaying IVF was the most cost-effective 
strategy in women younger than 38 
years of age. In women above 38 years 
of age, no diagnostic tubal patency 
test and immediate IVF was the most 
cost-effective strategy (Verhoeve et al., 
2013). However, these cost-effectiveness 
analyses did not take the type of contrast 
medium into account or the fertility-
enhancing effect of oil-based contrast. 
Nevertheless, recent studies have shown 
a fertility-enhancing effect of tubal 
flushing itself independent of the type of 
contrast medium. The effect was more 
prominent with an oil-based contrast 
medium (Dreyer et al., 2019; Wang et al., 
2019).
Implications for treatment can also be 
seen from the results of the current 
study. After 5 years of follow-up, HSG 
with oil-based contrast resulted in higher 
cumulative live birth rates compared 
with HSG with water-based contrast at 
an equivalent cost. The higher price of 
oil-based contrast was compensated by 
lower IVF or ICSI uptake in the oil group. 
More couples conceived naturally or by 
IUI after HSG with oil-based contrast, 
and fewer couples conceived by IVF or 
ICSI after HSG with oil-based contrast. 
This therefore suggests that offering 
women a tubal patency test using oil-
based contrast during fertility workup 
is a good first step before starting ART, 
especially in countries where ART is 
not reimbursed. The presumed higher 
chance of an ongoing pregnancy after 
HSG could prevent couples from the 
burdens of ART. Additionally, HSG is a 
relatively easy procedure and is less time-
consuming. This study's findings can thus 
be used for counselling infertile couples 
during fertility workup.
In conclusion, over a 5-year follow-up 
period, HSG with oil-based contrast 
had similar costs for a 5% increase in 
156 RBMO  VOLUME 42  ISSUE 1  2021
the ongoing pregnancy rate and a 7.5% 
increase in the live birth rate when 
compared with HSG with a water-based 
contrast.
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